TriSalus Life Sciences, Inc. (TLSI)
Nasdaq: TLSI · Surgical & Medical Instruments & Apparatus · Westminster, CO · filing with the SEC since 2020
Who owns TriSalus Life Sciences, Inc.
As filed with the SECHolders of 5% or more
5
Frankenius Equity AB holds 14% of Common Stock, $0.0001 par value, as its SCHEDULE 13D/A filed Aug 4, 2025 says.
Directors and officers
13
report now, of 30 people on the record since 2020. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Frankenius Equity AB
SCHEDULE 13D/A · filed Aug 4, 2025 · Common Stock, $0.0001 par value · 20.5% in May 2, 2025
First Light Asset Management, LLC
SCHEDULE 13G/A · filed Jul 7, 2026 · Common Stock, $0.01 par value · 8.75% in May 15, 2026
Mats Wahlstrom
SCHEDULE 13D/A · filed Aug 1, 2025 · Common Stock, $0.0001 par value · 9% in Dec 19, 2024
Utmost Group PLC
SCHEDULE 13G · filed May 12, 2026 · Common Stock · 6.79% in Nov 3, 2025
James J. Pallotta
SCHEDULE 13G/A · filed May 20, 2026 · Common Stock, Par Value $0.0001 per share
Nantahala Capital Management, LLC
SCHEDULE 13G/A · filed Nov 14, 2025 · Common stock, $0.0001 par value · reported falling below 5%, from 5.29% in Aug 14, 2025
What TLSI reports owning in othersstakes of 5% or more, and other ties
1 subsidiary in 1 country, from the list filed with the 10-K filed Apr 15, 2025.
Insider tradesForm 4
18sales
12purchases
0sales on a scheduled plan
5people selling
$100,000sold, in dollars
$3.6Mbought, in dollars
Open-market trades on Form 4 from Oct 7, 2025 to Oct 7, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 7, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window10 of 36 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Szela Mary T | CEO and President | 2 | $100,000 | 0 | 2 | $200,000 |
| Stansky Michael P | director | 0 | $0 | 0 | 4 | $3.0M |
| Patience David | Chief Financial Officer | 0 | $0 | 0 | 2 | $0 |
| Gordon Gary B. | director | 0 | $0 | 0 | 2 | $100,000 |
| Wahlstrom Mats | director | 0 | $0 | 0 | 1 | $200,000 |
| Valle William | director | 0 | $0 | 0 | 1 | $100,000 |
| Cox Bryan F. | Chief of Research | 4 | $0 | 0 | 0 | $0 |
| Marshak Richard | Chief Commercial Officer | 5 | $0 | 0 | 0 | $0 |
| Stevens Jennifer | Chief Regulatory Officer | 4 | $0 | 0 | 0 | $0 |
| Devlin Jodi | Chief of Clinical Operations | 3 | $0 | 0 | 0 | $0 |